Blueprint Medicines
The Senior Manager, Speaker Bureau Operations ensures the successful execution and continuous improvement of speaker bureau programs through cross-functional collaboration and operational excellence.
Headquarters
Cambridge, Massachusetts, United States
Company Size
501-1000 employees
Founded
2011
Blueprint Medicines is a biotechnology company focused on developing targeted therapies for patients with cancer and rare diseases. The company uses precision medicine and genomics to design drugs that selectively inhibit disease-causing proteins, particularly kinase-driven cancers and systemic mastocytosis.
Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies
4 days ago
Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis
2 weeks ago
Blueprint’s rare disease drug Ayvakit shows long-term benefit
1 week ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Blueprint Medicines.
57% above the average for this role
Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover
Jun 2, 2025